AUTHOR=Hou Jing-Yu , Xiao Ya-ting , Huang Jing-Bo , Jiang Xin-Hua , Jiang Kai , Li Xun , Xu Li , Chen Min-Shan 

TITLE=Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma

JOURNAL=Frontiers in Pharmacology

VOLUME=Volume 13 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.917384

DOI=10.3389/fphar.2022.917384

ISSN=1663-9812

ABSTRACT=Background:The RESORCE trial reported that regorafenib was effective as the second-line treatment for patients with hepatocellular carcinoma (HCC) after progression on sorafenib. Real-world data are needed to assess clinical outcomes and adverse events in the setting of daily practice.
Objective:We aimed to evaluate the efficacy and safety of regorafenib after disease progression with sorafenib in Chinese patients with advanced HCC.
Patients and methods: A total of 41 patients with advanced HCC who did not respond to sorafenib and followed a regorafenib regimen were enrolled in this retrospective study. Overall survival (OS), progression-free survival (PFS), radiological responses, and adverse events (AEs) were evaluated. Survival curves were compared by using the log-rank test and constructed with the Kaplan–Meier method.
Results: The median PFS with regorafenib was 6.6 months (range: 5.0-8.2 months), and the median OS was not reached. The 1-year OS rate of regorafenib was 66.4%. The median OS of sequential sorafenib-regorafenib treatment was 35.3 months (95% CI: 24.3-46.3), and the 2-year OS rate of sequential sorafenib-regorafenib treatment was 74.4%. The most frequent AEs during regorafenib treatment were  elevated aspartate aminotransferase (17/41 patients [41.5%]),  elevated alanine aminotransferase (16/41 patients [39%]) and hand-foot syndrome (14/41 patients [34.1%]).
Conclusions: Regorafenib seems safe and clinically efficacious in patients with advanced HCC who progressed on first-line sorafenib.